Nova Biomedical Introduces a New Generation Veterinary Critical Care Analyzer with Stat Profile® Prime Vet
FOR IMMEDIATE RELEASE: October 7, 2015
Contact: Brad Bullen
(781) 647-3700 ext. 570
Nova Biomedical Introduces a New Generation Veterinary Critical Care Analyzer
with Stat Profile® Prime Vet
Waltham, MA – Nova Biomedical is pleased to introduce Stat Profile Prime Vet, a new generation veterinary critical care analyzer that utilizes Nova’s innovative no-maintenance sensor card technology for a smaller, faster, and less expensive analyzer.
Prime Vet delivers a 10-test stat menu of pH, PCO2, PO2, Na, K, Cl, Ca, Glu, Lac, and Hct, offering veterinary providers the opportunity to improve profitability through in-house diagnostics. Veterinary providers may also benefit from Prime Vet’s open data interfacing and optional data management system to optimize billing.
Prime Vet’s no-maintenance technology comprises a single MicroSensor Card™ that contains all sensors with a 32-day use life, and a reagent cartridge containing all calibration reagents. The MicroSensor Card and reagent cartridge are both maintenance free and easily replaced in seconds. This design optimizes the life of each, improves analyzer uptime, and reduces costs.
Prime Vet’s Clot Block™ sample flow path protects the MicroSensor Card from blockages and downtime caused by blood clots. Complete quality monitoring is achieved through automated quality control that verifies analyzer accuracy and precision on assayed liquid controls, and supplemental quality monitoring that electronically monitors correct performance of all analytical components for each analysis.
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova’s biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests with over 12 unique instrument offerings for broad range of cell culture applications. Nova employs over 1,200 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, Spain, France, Switzerland, Germany, Italy, Japan, and Taiwan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S., Taiwan, and Brazil. www.novabiomedical.com